The Use of Combination Therapies to Treat Castration-Resistant Prostate Cancer 2.0
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2016
Special Issue Editor
Interests: peptide vaccines for the treatment of aggressive prostate cancer; TNBC and GBM
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of "The Use of Combination Therapies to Treat Castration-Resistant Prostate Cancer"
(https://www.mdpi.com/journal/cancers/special_issues/Hormone_Prostate).
The majority of prostate cancer cases are diagnosed while the cancer is still confined to the prostate and nearby organs, and the 5-year survival for men with this cancer is 100%. This rate is, however, reduced by a third if, at the time of diagnosis, the cancer has already spread to other parts of the body. Standard therapy for organ-confined prostate cancer includes active surveillance, external beam radiotherapy, and brachytherapy and radical prostatectomy. The treatment of metastatic disease involves androgen deprivation therapy (ADT) and either possibly up-front docetaxel chemotherapy or abiraterone or, upon progression, the subsequent addition of anti-androgens (abiraterone or enzalutamide) to ADT. Prolonged ADT and sequential therapies promote the development of a neuroendocrine prostate cancer phenotype (NEPC). NEPC is characterized by loss of AR expression and resistance to hormonal therapies. NEPC is a poorly defined clinical phenotype of aggressive disease and causes approximately 10–25% of prostate-cancer-related deaths.
Although the emergence of immunotherapeutic approaches has delivered significant benefits across a range of immunogenic tumors, the same impact has yet to be seen for prostate cancer, for which there are a number of potential reasons, including the establishment of an immunosuppressive TME which can be driven, at least in part, by the presence of MDSCs, depression, and chronic cellular stress. Notwithstanding this, evidence supports the concept that inducing immunity to prostate-related proteins such as prostatic acid phosphatase (PAP) can be of therapeutic benefit.
Therefore, improving the efficacy of immunotherapies requires approaches to attenuate the immunosuppressive nature of the TME, to take into account the different immunological challenge of NEPC and the impact of depression or chronic stress.
This Special Issue will take a closer look at the latest immunotherapy treatments being assessed to treat hormone-resistant prostate cancer with a focus on NEPC.
Dr. Stephanie McArdle
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hormone-resistant prostate cancer
- NEPC
- immunotherapy
- combination therapy
- castration-resistant prostate cancer
